1. Home
  2. NFGC vs DSGN Comparison

NFGC vs DSGN Comparison

Compare NFGC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Found Gold Corp

NFGC

New Found Gold Corp

HOLD

Current Price

$2.06

Market Cap

760.5M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$10.47

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFGC
DSGN
Founded
2016
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
760.5M
819.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
NFGC
DSGN
Price
$2.06
$10.47
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.25
AVG Volume (30 Days)
1.3M
1.1M
Earning Date
05-11-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3,542.00
N/A
Revenue Next Year
$118.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$3.33
52 Week High
$3.59
$17.25

Technical Indicators

Market Signals
Indicator
NFGC
DSGN
Relative Strength Index (RSI) 50.96 37.06
Support Level $1.85 $9.36
Resistance Level $2.14 $10.59
Average True Range (ATR) 0.11 1.29
MACD -0.00 -0.38
Stochastic Oscillator 43.53 6.83

Price Performance

Historical Comparison
NFGC
DSGN

About NFGC New Found Gold Corp

New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Companies exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: